Ipsen CEO Outlines Strategy For Long-Term Success

Backed With €3bn Warchest

While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.

A professional businessman thinking while standing on a black arrow pointing forward in grey space concept
NEw CEO Loew Plotting Ipsen's next steps • Source: Archive

Five months after taking the helm at Ipsen SA, CEO David Loew has laid out his strategic priorities for the French drugmaker to Scrip which will involve maximizing core brands Somatuline, Decapeptyl and Dysport, realizing the full potential of the oncology products Cabometyx and Onivyde, and upping its focus on external innovation.

One of the first moves by Loew, who previously headed up the Sanofi Pasteur vaccines business before taking over...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.